4/14
10:34 am
oncy
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz [Globe and Mail, The (Toronto, Canada)]
Low
Report
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz [Globe and Mail, The (Toronto, Canada)]
4/10
06:09 pm
oncy
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
High
Report
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
4/10
07:13 am
oncy
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers [Yahoo! Finance]
Low
Report
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers [Yahoo! Finance]
4/10
07:00 am
oncy
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Low
Report
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
3/10
02:44 pm
oncy
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at Maxim Group from $5.00 to $3.00. They now have a "buy" rating on the stock.
Low
Report
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at Maxim Group from $5.00 to $3.00. They now have a "buy" rating on the stock.
3/10
01:37 pm
oncy
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
3/10
01:15 pm
oncy
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at Royal Bank of Canada from $6.00 to $5.00. They now have an "outperform" rating on the stock.
Low
Report
Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at Royal Bank of Canada from $6.00 to $5.00. They now have an "outperform" rating on the stock.
3/8
07:45 am
oncy
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge [Globe and Mail, The (Toronto, Canada)]
High
Report
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge [Globe and Mail, The (Toronto, Canada)]
3/7
11:12 am
oncy
https://seekingalpha.com/article/4765729-oncolytics-biotech-inc-oncy-q4-2024-earnings-call-transcript [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4765729-oncolytics-biotech-inc-oncy-q4-2024-earnings-call-transcript [Seeking Alpha]
3/7
07:07 am
oncy
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 [Yahoo! Finance]
Medium
Report
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 [Yahoo! Finance]
3/7
07:00 am
oncy
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
Medium
Report
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
2/27
10:15 am
oncy
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 [Globe and Mail, The (Toronto, Canada)]
2/25
12:45 pm
oncy
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights [Globe and Mail, The (Toronto, Canada)]
Low
Report
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights [Globe and Mail, The (Toronto, Canada)]
2/25
07:30 am
oncy
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights [Globe and Mail, The (Toronto, Canada)]
Low
Report
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights [Globe and Mail, The (Toronto, Canada)]
2/25
07:00 am
oncy
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Low
Report
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
2/19
10:21 am
oncy
Investors Eye Biotech Sector as Cancer Therapy Market Surges [Globe and Mail, The (Toronto, Canada)]
Low
Report
Investors Eye Biotech Sector as Cancer Therapy Market Surges [Globe and Mail, The (Toronto, Canada)]
2/19
10:17 am
oncy
Investors Eye Biotech Sector as Cancer Therapy Market Surges [Globe and Mail, The (Toronto, Canada)]
Low
Report
Investors Eye Biotech Sector as Cancer Therapy Market Surges [Globe and Mail, The (Toronto, Canada)]
2/19
07:23 am
oncy
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 [Yahoo! Finance]
Medium
Report
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 [Yahoo! Finance]
2/19
07:00 am
oncy
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
Medium
Report
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
2/18
07:30 am
oncy
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer [Yahoo! Finance]
Low
Report
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer [Yahoo! Finance]
2/18
07:01 am
oncy
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer [Globe and Mail, The (Toronto, Canada)]
2/18
07:00 am
oncy
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Low
Report
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
2/14
06:09 pm
oncy
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency [Yahoo! Finance]
Low
Report
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency [Yahoo! Finance]
2/14
05:15 pm
oncy
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Low
Report
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
2/7
09:53 pm
oncy
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence [Globe and Mail, The (Toronto, Canada)]
Low
Report
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence [Globe and Mail, The (Toronto, Canada)]